Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes

Clinical Immunology : the Official Journal of the Clinical Immunology Society
Christian PflegerHvidøre Study Group on Childhood Diabetes

Abstract

Th1 related chemokines CCL3 and CCL5 and Th2 related CCL4 as ligands of the receptor CCR5 contribute to disease development in animal models of type 1 diabetes. In humans, no data are available addressing the role of these chemokines regarding disease progression and remission. We investigated longitudinally circulating concentrations of CCR5 ligands of 256 newly diagnosed patients with type 1 diabetes. CCR5 ligands were differentially associated with beta-cell function and clinical remission. CCL5 was decreased in remitters and positively associated with HbA1c suggestive of a Th1 associated progression of the disease. Likewise, CCL3 was negatively related to C-peptide and positively associated with the beta-cell stress marker proinsulin but increased in remitters. CCL4 associated with decreased beta-cell stress shown by negative association with proinsulin. Blockage of chemokines or antagonism of CCR5 by therapeutic agents such as maraviroc may provide a new therapeutic target to ameliorate disease progression in type 1 diabetes.

References

Jul 24, 1986·The New England Journal of Medicine·H Yki-Järvinen, V A Koivisto
Feb 12, 1998·The New England Journal of Medicine·A D Luster
Jul 31, 2001·Lancet·M A Atkinson, G S Eisenbarth
Jul 30, 2002·Diabetes·Reza AbdiMohamed H Sayegh
Feb 10, 2004·European Journal of Immunology·Carla Carvalho-PintoCarlos Martínez-A
Jan 26, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·P Hanifi-MoghaddamN C Schloot
Nov 30, 2006·Annals of the New York Academy of Sciences·Mohamed M Jahromi, George S Eisenbarth
Dec 8, 2006·Annals of the New York Academy of Sciences·Kerstin KempfHubert Kolb
Mar 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·N C SchlootT Mandrup-Poulsen
Oct 10, 2007·Statistics in Medicine·Ruth M Pickering, Mark Weatherall

❮ Previous
Next ❯

Citations

May 18, 2011·BMC Medical Genomics·Georgina V BixlerWillard M Freeman
Mar 22, 2014·The Journal of Antimicrobial Chemotherapy·Laura Pérez-MartínezJosé-Ramón Blanco
Nov 26, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Christian PflegerMichael Eckhard
Sep 12, 2009·Journal of Autoimmunity·Christian PflegerUNKNOWN p520/521 Study Group
Sep 23, 2009·Diabetes/metabolism Research and Reviews·Simona CerneaUNKNOWN D-Cure Workshop
Apr 23, 2013·Clinical and Experimental Immunology·M C SimonN C Schloot
Jun 19, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jacen S Maier-MooreR Hal Scofield
Oct 16, 2012·Brain Research Bulletin·Guilin LiShangdong Liang
May 7, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Linda AkermanRosaura Casas
Jul 15, 2016·Pediatric Diabetes·Flemming PociotLotte B Nielsen
Apr 9, 2009·Nature Reviews. Endocrinology·Décio L EizirikFernanda Ortis
Jan 26, 2010·Nature Reviews. Immunology·Bart O Roep, Mark Peakman
May 31, 2014·American Journal of Physiology. Gastrointestinal and Liver Physiology·Ramona PaisThomas Skurk
Jul 26, 2019·Diabetes/metabolism Research and Reviews·Ting ZhongZhiguang Zhou
Jun 10, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Hanan Aly, Peter Gottlieb
Jul 1, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.